|
|
 |
|
Viewing report
|
|
|
|
G-Protein Coupled Receptors (GPCRs): Technical Overview, Emerging Technologies, Market Trends & Opportunities, 2nd Edition
Drug and Market Development Publishing, March 2005, Pages: 132
G Protein-Coupled Receptors (GPCRs) account for 50% of the current drug targets, and remain about one-third of the drug discovery effort in the drug discovery-development community. As a result of the sequencing of the human genome, more than 150 orphan and non-chemosensory GPCRs have been identified for which their cognate ligands or biological functions are unknown. De-orphanization of those receptors could bring novel therapeutic targets to the industry against which novel therapeutics could be designed.
In addition, current GPCR-based drugs only target ~30% of the approximately 200 known GPCRs in the genome. This is a rich target class that is highly-druggable. This Report will benefit those companies, institutions, and individuals requiring an in-depth and thorough analysis of the technical areas in GPCRs, the emerging technologies in this space, as well as qualitative and quantitative market analyses, trends, and attendant business opportunities. Further, this Report provides thorough profiles of those companies currently active within the GPCR space.
About the Author
Enal S. Razvi, Ph.D. Dr. Enal Razvi is currently biotechnology business development consultant based in the San Francisco Bay Area. Previously Dr. Razvi served as Vice President at DiscoveRx Corporation in Fremont, California. Before DiscoveRx, at LJL BioSystems (Sunnyvale, CA), Dr. Razvi served as Senior Director of Business Development and played a major role in developing LJL BioSystems' SNP genotyping business.
Subsequent to the acquisition of LJL BioSystems by Molecular Devices Corporation, Dr. Razvi ran Molecular Devices' Genomics business. Prior to LJL, while at Frost & Sullivan, Dr. Razvi served as Director of their Drug Discovery Consulting business. Dr. Razvi holds a doctorate in biomedical sciences from the University of Massachusetts Medical School, and completed post-doctoral work at The Rockefeller University in New York and at Harvard Medical School. Fang Ye, Ph.D. Dr. Fang is a Research Associate at Corning Incorporated in Corning, NY.
He currently serves as a technical leader for research and development projects relating to novel assay technologies for drug discovery based upon innovations. Prior to joining the Corning, Dr. Fang was a postdoctoral associate conducting basic research with an emphasis in the area of the assembly of biological molecules at Johns Hopkins University School of Medicine, and at the University of Vermont. Dr. Fang holds a doctorate in biophysical chemistry from the Institute of Chemistry of the Chinese Academy of Sciences, Beijing, China.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
GPCR - Drug Targets
Ion Channels and G Protein-coupled Receptors (GPCRs) Qualitative and Quantitative Analysis
Market Opportunity in the G-Protein Coupled Receptors (GPCRs) Target Space: Qualitative and Quantitative Market Metrics
G-Protein Coupled Receptors (GPCRs) 2007 Market Report
Gpcrs: The Targets of Today's Drugs and Tomorrow's Blockbusters
Cell-Based Assays for Drug Discovery
G Protein-coupled Receptors: Molecular Pharmacology
Coupled Bioluminescent Assays: Methods, Evaluations, and Applications
Ion Channel Assays in the Drug Discovery Process
Drug Discovery Tools for High-Content Analysis
Model Organisms in Drug Discovery and Development: An Industry Analysis
Development of Cell-Based Assays (Technical Insights)
|
|
|
|
